This study aimed to compare the bone mineral density (BMD) of patients with ulcerative colitis (UC) and Crohn's disease (CD) in order to determine the possible risk factors for bone loss. A total of 142 patients with UC (n = 88) and CD (n = 54) participated in the study. They were assessed for gender, body mass index (BMI), disease duration and activity, intestinal site of involvement, history of bowel resection, use of steroids, and extraintestinal findings and complications. The BMD was measured by dual-energy X-ray absorptiometry. There were no differences in BMD between UC and CD patients. In UC patients, BMI showed a significant positive correlation with BMD. Femoral neck Z scores were lower in patients with extra-intestinal findings and complications. Steroid use, disease activity, disease localization, disease duration, bowel surgery and gender had no influence on BMD. Complications or extra-intestinal involvement were a significant predictor for BMD in both groups.
Introduction
In patients with inflammatory bowel disease (IBD), the prevalence of low bone mineral density (BMD) (32 -77%) is higher than in normal subjects. 1, 2 Low BMD in IBD can be seen both in males and females, and may occur in relatively young patients. 3 Osteoporosis is an important cause of morbidity because of the increased risk of fragility fractures; the fracture risk reported in Crohn's disease (CD) is 6%. 4, 5 Osteoporosis is also frequently observed in CD patients with small intestinal involvement due to malabsorption of calcium and vitamin D, and due to the use of corticosteroids. 6 -8 The aetiology of low BMD in patients with IBD is believed to be highly related to the use of corticosteroids. 3 Corticosteroids may not, however, be the only reason for low BMD, as these agents are generally only used in IBD S Poturoglu, F Balkan, ZE Karaali et al.
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patients at high doses for a short period of time, followed by a rapid decrease in the dose. Factors including calcium balance disorders, malabsorption and vitamin D deficiencies, lack of sex hormones, inflammatory cytokines and low body mass index (BMI), can also contribute to this multifactorial process. 3 The World Health Organization (WHO) considers osteoporosis to be a silent epidemic characterized by susceptibility to bone fragility and increased risk of fractures due to degeneration of the microstructure of the bone mass and osseous tissue. 9 This silent disease increases the rate of morbidity in IBD. 3 It is, therefore, important to identify the risk factors for osteoporosis in IBD patients.
The present study was designed to evaluate possible risk factors for osteoporosis, including the duration and activity of disease, localization of gastrointestinal involvement, BMI, gender, prior operations, use of steroids or immunosuppressive drugs, and complications or extra-intestinal involvement in patients with IBD, and to compare the BMD of patients with ulcerative colitis (UC) and CD. 
Patients and methods PATIENTS

STUDY DESIGN AND ASSESSMENTS
Each patient was assessed for gender, BMI, disease duration, disease activity, intestinal site of involvement, prior operation status, use of steroids, and complications or extraintestinal involvement. The relationship between these parameters and BMD was investigated, and the BMD measurements for UC and CD patients were compared.
All patients underwent anterior-posterior bone mineral densitometry of the spine (lumbar) and femoral neck using dualenergy X-ray absorptiometry (DEXA) (Lunar DEXA DPX-IQ 4.8a; GE Lunar Corp., Madison, WI, USA): the values were given as T and Z scores. Patients were considered to have normal BMD if the T score was > -1, to have osteopenia if the score was between -1 and -2.5, and to have osteoporosis if the score was < -2.5. 10 The BMI of the patients was calculated as body weight divided by the square of the height (kg/m 2 ). Patients were considered to have a low body weight if their BMI was < 18 kg/m 2 , a normal body weight if their BMI was 18 -25 kg/m 2 , to be overweight if their BMI was 25 -30 kg/m 2 , to be obese if their BMI was 30 -40 kg/m 2 , and to be morbidly obese if their BMI was > 40 kg/m 2 .
The UC clinical activity index of Seo et al. 11 and the Harvey-Bradshaw CD clinical activity index 12 were used to evaluate disease activity.
STATISTICAL ANALYSIS
All statistical analyses were undertaken using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Results are given as mean ± SD.
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The Student's t-test or the Mann-Whitney Utest, a non-parametric test, were used to detect whether there was a difference between the means of either independent group. The latter was used when the SD was greater than the mean and/or the patient number in the groups was small. Analysis of variance was used to compare the means of more than two groups and a non-parametric method, the χ 2 test, was used to compare between the groups. Pearson's correlation coefficient was employed to measure the degree of correlation between two variables. Regression analysis was undertaken to test for possible associations between variables, including duration of disease, gender, BMI, cumulative steroid dose and prior operation status. In all analyses, a P-value < 0.05 was considered to be statistically significant.
Results
A total of 142 patients with IBD were enrolled in the study: 88 were UC patients (48 males) and 54 had CD (28 males). The mean ± SD age was 35.95 ± 11.50 years (range 20 -59 years) amongst UC patients and 34.07 ± 8.64 years (range 20 -60 years) amongst CD patients. The mean ± SD BMI was 26.45 ± 5.13 kg/m 2 (range 18 -41 kg/m 2 ) for UC patients and 24.00 ± 4.25 kg/m 2 (range 18 -34 kg/m 2 ) for CD patients. There were no significant differences between the groups regarding gender, mean age and BMI. Osteopenia was detected in 34 (38.6%) UC patients, and 10 (18.5%) CD patients, and two (3.7%) CD patients had osteoporosis. Among all patients, 44 (31.0%) had osteopenia and 2 (1.4%) had osteoporosis.
No significant differences were found in the femoral neck T and Z scores and the lumbar T and Z scores between CD and UC patients ( Fig. 1) . Similarly, there were no significant differences between males and females in the UC and CD groups in terms of BMD measurements. In the UC group, the femoral neck T score (mean ± SD -0.21 ± 0.20, r = 0.32, P = 0.039), the femoral neck Z score (mean ± SD -0.48 ± 0.19, r = 0.43, P = 0.004) and the lumbar Z score (mean ± SD of -0.20 ± 0.19, r = 0.30, P = 0.049) significantly 
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increased along with increasing BMI. A similar relationship was not observed for the lumbar T score in the UC group or for any of the T and Z scores in CD patients.
The mean ± SD disease activity, using the UC clinical activity index of Seo et al., 11 was 112 ± 34 in UC patients. Although BMD was smaller in those with a disease activity > 150, there was no significant relationship between BMD and disease activity (P > 0.05). In CD patients, the mean ± SD disease activity using the Harvey-Bradshaw CD clinical activity index 12 was 4.0 ± 1.8. No significant relationship between disease activity and BMD was found in this group.
In terms of the localization of gastrointestinal involvement in UC patients, 44 (50%) were rectosigmoid, 14 (16%) were left colon and 30 (34%) were pancolitis. Twenty-six (48%) CD patients had terminal ileum and 28 (52%) had ileocolonic involvement. No significant relationship was found between the localization of the involved part of the intestine and BMD in either group.
The mean ± SD disease duration was 35.04 ± 11.02 months in CD patients and 34.74 ± 8.64 months in UC patients. No significant correlation was found between disease duration and BMD.
Extra-intestinal involvement was present in 10 (11%) UC patients and complications or extra-intestinal involvement were observed in 20 (37%) patients with CD (Table  1) . When patients with UC and CD were evaluated together, a total of 30 (21%) patients showed complications or extraintestinal involvement. Femoral neck Z scores were significantly lower in patients with complications or extra-intestinal involvement compared with patients who did not have complications or extraintestinal involvement (P = 0.015) ( Table 2) .
Two patients (2.3%) in the UC group and 10 (18.5%) CD patients had a previous history of surgery. Among the UC patients, there was one right hip prosthesis surgery and one total colectomy. Among the CD patients, there were three appendectomy, two fistulotomy plus tractus excision, two appendectomy plus fistula tractus repair, one appendectomy plus fistula repair plus partial ileum resection, and two appendectomy plus right hemicolectomy plus fistula tractus. No relationship was found between previous surgery and BMD.
A total of 12 (13.6%) UC patients and 42 (77.8%) CD patients had used cumulative steroid doses of 2 g for ≥ 1 month. No relationship was found between steroid use and BMD in either group. Sixty-eight (47.9%) patients were taking azathioprine and no relationship was found between the use of this agent and BMD.
TABLE 1: Complications or extra-intestinal involvement in the patients with inflammatory bowel disease in this study
Complications or extra-intestinal
Ulcerative colitis Crohn's disease Total involvement n = 88 n = 54 n = 142 Arthralgia 6 (7) 8 (15) 14 (10) Arthritis 4 (5) 2 (4) 6 (4) Fistula 0 6 (11) 6 (4) Peri-anal disease 0 4 (7) 4 (3) Total 10 (11) 20 (37) 30 (21) Data show number (%) of patients.
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Discussion
Both malabsorption and pro-inflammatory cytokines released due to bowel inflammation contribute to osteoporosis associated with IBD. 13 In a group of CD patients with a mean age of 40 years, 15% had osteoporosis and 50% had osteopenia. 14 The risk of osteoporosis was higher in those who received the CD diagnosis before the age of 18 years. 14 Considering that the mean age of the patients in the present study was 35.95 ± 11.50 years and the mean disease duration was 35.04 ± 11.02 months, it would seem likely that IBD developed after the age of 18 in this patient cohort. Osteopenia was detected in 38.6% of UC patients, and 3.7% of CD patients had osteoporosis and 18.5% had osteopenia. Among all patients, 31.0% had osteopenia and 1.4% had osteoporosis.
In a study by Jahnsen et al., 15 Z scores for CD patients were lower compared with UC patients and healthy subjects. In the same study, the BMD measurements for UC patients were similar to those of the healthy group. The mean Z scores for both groups in the present study were within normal ranges for lumbar vertebrae and femoral neck.
The BMI is an important risk factor affecting BMD changes in both CD and UC groups. 15 BMI reflects the nutritional status and it has been shown that BMD decreases with decreasing BMI. 16, 17 In the Framingham Study of osteoporosis, 17 a negative correlation was detected between BMI and osteoporosis, indicating that the frequency of osteoporosis was lower in subjects with a higher BMI. 17 In another study by Martin et al., 18 a relationship was seen between mean Z scores and low BMI or high-dose steroid use. No relationship was seen between T scores and low BMI or high-dose steroid use. 18 The present study showed Z scores to be reliable indicators of BMD measurements in IBD. In UC patients a positive correlation was also found between BMI and femoral neck Z and T and lumbar Z scores, and BMD was lower in patients with a low BMI. This was not observed in patients with CD. Jahnsen et al. 15 showed that gender affected BMD in both UC and CD patients, although no relationship was demonstrated between gender and BMD in either group in the present study.
The cumulative steroid dose used for a patient is important in the development of osteoporosis. For example, in a trial by Scharla et al., 19 BMD measurements were shown to decrease in CD patients taking 10 g of steroids. In another study by Silvennoinen et al., 20 subjects taking a cumulative steroid dose of 10 g had lower BMD levels compared with those taking ≤ 5 g, while no low BMD values were seen in the group not taking 20 Lumbar vertebrae and femoral neck BMD values have been shown to be significantly decreased in subjects taking a high cumulative steroid dose (18 g). 21 It is possible, however, that this is not related to the use of steroids, as these agents are generally only used as short-term, high-dose therapy in IBD patients followed by a rapid decrease in the dose. It is unlikely that steroid use is the only risk factor in patients who are taking high-dose steroids; disease activity and malabsorption are also more pronounced in these patients. 14 No relationship was found between the use of a cumulative steroid dose of 2 g for ≥ 1 month and BMD in patients in the present study. This is probably because the steroid dose used was low. Other factors, including calcium balance disorders, malabsorption, vitamin D deficiencies, lack of sex hormones, inflammatory cytokines and low BMI can also contribute to this multifactorial process. 3 The study by Jahnsen et al. 22 demonstrated that the decrease in BMD in IBD patients was multifactorial and that it was very difficult to investigate the effect of each factor separately. Nevertheless, disease activity and steroid therapy reduced BMD in patients with CD. 22 In a separate study, the lumbar and femoral neck Z scores were higher in UC and CD patients that were in remission compared with those patients with active disease. 23 No relationship was found between disease activity and BMD in the present study; this may be because most of the patients had mild disease activity.
Malabsorption seen in IBD patients is a major cause of bone loss. 24, 25 In the study by Frei et al., 14 the subjects were compared according to age, steroid and azathioprine use, bowel resection, and BMI. Their study demonstrated that steroid use and bowel resection were important risk factors for lumbar osteoporosis. In patients in the present study, no relationship was found between azathioprine use and BMD.
In the study by Jahnsen et al., 15 BMD measurements were similar in subjects with colon or ileum involvement. In the same study, no difference in BMD measurements was found in groups with or without small intestinal resection. No relationship was found between the localization of the involved intestine and BMD measurements in UC patients. 15 The present study also demonstrated that there was no difference between the BMD measurements of subjects who had or had not undergone prior operations. Similarly, no relationship was found between the localization of the involved intestine and BMD measurements in CD and UC patients, but femoral neck Z scores were much lower in IBD patients with complications and extra-intestinal involvement (21% of patients) compared to those patients without these clinical findings.
In conclusion, a significant relationship with BMD was only found for BMI and the presence of complications and extraintestinal involvement. No significant relationship was found between BMD and gender, disease duration, disease activity, steroid use, localization of the involved intestine or bowel surgery. These findings might have occurred because of the small sample size and the low level of disease activity. Results from previous studies are contradictory. Thus, the relationship between osteoporosis and IBD should be investigated further in controlled studies comprising a greater number of patients.
